HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Hugo Maia Selected Research

Oral Contraceptives

1/2014The effect of pycnogenol on patients with dysmenorrhea using low-dose oral contraceptives.
1/2013Combining oral contraceptives with a natural nuclear factor-kappa B inhibitor for the treatment of endometriosis-related pain.
1/2013The effect of oral contraceptives on aromatase and Cox-2 expression in the endometrium of patients with idiopathic menorrhagia or adenomyosis.
11/2012Role of inflammation and aromatase expression in the eutopic endometrium and its relationship with the development of endometriosis.
1/2012Advantages of the association of resveratrol with oral contraceptives for management of endometriosis-related pain.
4/2010Activation of NF-kappaB and COX-2 expression is associated with breakthrough bleeding in patients using oral contraceptives in extended regimens.
12/2008Effect of oral contraceptives on vascular endothelial growth factor, Cox-2 and aromatase expression in the endometrium of uteri affected by myomas and associated pathologies.
3/2008The effect of oral contraceptives on aromatase expression in the eutopic endometrium of patients with endometriosis.
6/2007Aromatase expression in the eutopic endometrium of myomatous uteri: the influence of the menstrual cycle and oral contraceptive use.
10/2006Effect of the menstrual cycle and oral contraceptives on aromatase and cyclooxygenase-2 expression in adenomyosis.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Hugo Maia Research Topics

Disease

10Endometriosis (Adenomyosis)
01/2013 - 11/2003
5Hemorrhage
01/2014 - 11/2003
4Inflammation
01/2013 - 04/2009
4Menorrhagia
01/2013 - 11/2003
4Amenorrhea
11/2012 - 11/2003
4Polyps
09/2007 - 11/2004
3Pain (Aches)
01/2014 - 01/2012
3Dysmenorrhea (Menstrual Pain)
01/2014 - 01/2012
3Endometrial Hyperplasia
09/2007 - 09/2002
2Metrorrhagia (Spotting)
01/2013 - 04/2010
2Infertility (Sterility)
01/2012 - 04/2009
2Myoma
12/2008 - 06/2007
2Hyperplasia
03/2003 - 09/2002
1Chronic Disease (Chronic Diseases)
01/2013
1Uterine Hemorrhage (Uterine Bleeding)
01/2013
1Fibrosis (Cirrhosis)
11/2012
1Menstruation Disturbances
11/2012
1Pelvic Pain
01/2012
1Osteoporosis
08/2006

Drug/Important Bio-Agent (IBA)

11Oral ContraceptivesIBA
01/2014 - 02/2006
11Aromatase (CYP19)IBA
01/2013 - 04/2006
6GestodeneIBA
01/2014 - 10/2006
6Cyclooxygenase 2 (Cyclooxygenase-2)IBA
01/2013 - 12/2005
5Estrogens (Estrogen)FDA Link
11/2012 - 09/2002
4drospirenoneFDA LinkGeneric
01/2013 - 02/2010
3HormonesIBA
01/2014 - 12/2005
2pycnogenolsIBA
01/2014 - 01/2013
2EnzymesIBA
01/2013 - 11/2012
2NF-kappa B (NF-kB)IBA
01/2013 - 04/2010
2Progestins (Progestagens)IBA
11/2012 - 04/2009
2Levonorgestrel (Plan B)FDA LinkGeneric
01/2012 - 11/2003
2Combined Oral ContraceptivesIBA
04/2010 - 12/2008
1resveratrolIBA
01/2012
1Danazol (Azol)FDA LinkGeneric
04/2009
1Dinoprostone (PGE2)FDA Link
04/2009
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
12/2008
1ProgesteroneFDA LinkGeneric
12/2008
1Testosterone (Sustanon)FDA Link
09/2007
1Ethinyl Estradiol (Estinyl)FDA LinkGeneric
10/2006
1ParaffinIBA
10/2006
1ProstaglandinsIBA
02/2006
1TamoxifenFDA LinkGeneric
12/2005
1tiboloneIBA
12/2005
1Proteins (Proteins, Gene)IBA
11/2004
1Estradiol (Estrace)FDA LinkGeneric
03/2003

Therapy/Procedure

1Female Contraceptive Devices (Vaginal Ring)
04/2009
1Contraception (Birth Control)
10/2006
1Complementary Therapies (Alternative Medicine)
08/2006
1Intrauterine Devices (Intrauterine Device)
11/2003